TAB1

Across TCGA pan-cancer cohorts, TAB1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TAB1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TAB1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAB1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

OV, PDAC, and LUAD are the cancer types where TAB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.612	0.922	.030	8	view →
PDAC	DFS	Median	III,IV	0.262	0.460	.017	4	view →
LUAD	DFS	Quartile	All	0.754	0.403	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TAB1–OV (DFS)

Open the OV breakdown →